ClinicalTrials.gg
CompletedNCT06336135Updated Dec 12, 2025

Reduction in Symptoms After Laser Therapy With Acorn aHFS

An observational study in Skin Aging, sponsored by Acorn Biolabs Inc.. Completed at 1 site in Canada. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-12.

Sponsored by Acorn Biolabs Inc. · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
11
Ages
18 Years to 60 Years
Sex
All
01

Study summary

This study evaluates the severity and duration of symptoms experienced after laser therapy comparing four post-procedure topical products. Each product is applied to an individual region of interest (5 cm diameter) on the back or décolleté according to randomization code after laser therapy. The subject, blind to the product applied to each of 4 regions of interest, assesses eight symptoms daily for 14 days. Photography is performed daily.

02

Conditions studied

  • Skin Aging

Keywords

  • skin, aging, rejuvenation, laser resurfacing, autologous secretome
03

In context

Lead sponsor

Acorn Biolabs Inc. is the lead sponsor of 5 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Subjects are healthy adults receiving laser skin rejuvenation therapy.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or Female
  • Age: ≥18 and ≤60 years
  • Any skin tone Fitzpatrick score 1-2 (light), 3-4 (medium), 5-6 (dark)
  • Competent and willing to provide written, to participate in all study activities

Exclusion criteria

Exclusion Criteria:

  • Pregnant women
  • Are participating/have participated in another interventional clinical trial in the last 30 days which may confound the results of this study, unless approved by Sponsor
  • Use of retinoids 7 days prior to the procedure
  • Active cutaneous infections in the treatment area
  • Diseases that could inhibit healing, such as scleroderma, or other cutaneous conditions that could confound study results
  • Subjects unable to communicate with the investigator and staff
  • Any health condition that in the investigator's opinion should preclude participation in this study
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
11 participants (actual)
Patient registry
No

Interventions

  • Otherautologous hair follicle derived secretome

    aHFS is a cosmetic topical intended to be applied to the human body after skin resurfacing cosmetic procedures. aHFS is produced from the plucked hair follicles of each individual, making it autologous.

    Also known as: Acorn autologous hair follicle secretome, aHFS

06

What researchers measure

Primary outcomes

  1. Reduction in severity and duration of symptoms

    Each region of interest will be evaluated daily for the severity and duration of eight symptoms

    Time frame: 2 weeks

07

Study locations

1 site
  • Rejuuv Medi Spa
    Markham, Ontario L3R0M3, Canada
08

References and documents

Individual participant data

Plan to share: No — Individual participant data will not be made available.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2024 to primary completion in Dec 2025, 20 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 22, 2024
First posted
Mar 28, 2024
StartActual
Mar 25, 2024
Primary completionActual
Dec 2, 2025
CompletionActual
Dec 2, 2025
Last update
Dec 12, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 12, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06336135
Lead sponsor
Acorn Biolabs Inc.
Responsible party
Sponsor
First posted
Mar 28, 2024
Start date
Mar 25, 2024
Primary completion
Dec 2, 2025
Completion
Dec 2, 2025
Last update
Dec 12, 2025

Study contacts

Lisa Campbell, PhD
study director · Acorn Biolabs Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion